The key point is that this is the first randomized, placebo-controlled clinical evidence that a GLP-1 receptor agonist may slow the biological processes associated with aging in humans. Michael Corley, PhD Using multiple epigenetic clocks, we saw a broad pattern of slower biological aging in participants treated with semaglutide compared with placebo, including a 9% slowing in the pace of aging measured by DunedinPACE and a significant effect on PCGrimAge, which tracks processes linked to all-cause mortality and age-related disease, the researcher detailed
The success of GLP-1 receptor agonists has not revealed new principles of endocrinology
But how does it compare to Mounjaro, the current champion
On the one hand, these drugs show promise in addressing obesity and its related comorbidities, potentially reducing long-term healthcare costs
They are the protocol
When your body has low levels of glutathione, you might feel weaker than usual, become less attentive, and observe alterations in your skin and digestion